Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular events

Eli Lilly's registry updates this week centered on a major cardiovascular outcomes trial readout, with several earlier-phase and post-marketing studies also updated.

• SURPASS-CVOT (NCT04255433), a completed Phase 3 trial comparing tirzepatide to dulaglutide in participants with type 2 diabetes, had results first posted on 2026-07-08. The trial assessed the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk¹, enrolling 13299 participants (actual)¹.
• RA-BRANCH (NCT04086745), a completed Phase 3b/4 study of baricitinib in rheumatoid arthritis, also had results first posted this week. The study was designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis², with enrollment of 1050 participants (actual)².
• NCT03929744, a completed Phase 1 single- and multiple-ascending dose study of LY3502970 in healthy subjects, had results first posted this week. The study has 5 parts (A, B, C, D, and E) and enrolled 133 participants (actual)³.
• NCT05841238, a completed Phase 1 multiple dose study of tablet and capsule formulations of LY3502970 in healthy overweight and obese participants, had results first posted this week. It evaluated how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food⁴, enrolling 52 participants (actual)⁴.
• NCT02009449 (IVY), a completed Phase 1 dose escalation study of pegilodecakin in advanced solid tumors, had results first posted this week. The trial was an open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy⁵, with 353 participants (actual)⁵ enrolled.
• Willow 2 (NCT03381547), a completed Phase 1 crossover pharmacokinetics study of pegilodecakin in healthy adults, had results first posted this week, enrolling 12 participants (actual)⁶.
• NCT07691489, a Phase 2 trial of trastuzumab deruxtecan plus cetuximab in HER2-low colorectal cancer, was newly posted and is not yet recruiting. Lilly is a collaborator; the trial is sponsored by Memorial Sloan Kettering Cancer Center, with AstraZeneca also collaborating, and aims to enroll 27 participants (estimated)⁷.
• INSIGHT-IBD (NCT07686757), a Phase 4 observational-style pragmatic study of mirikizumab in inflammatory bowel disease, is enrolling by invitation. Lilly is a collaborator; the study is sponsored by Specialty Networks Research and aims to enroll 400 participants (estimated)⁸, evaluating whether treatment with mirikizumab reduces the proportion of patients requiring an increase in IBD disease management⁸.